Cell & Gene Therapy

A comprehensive approach to cell and gene therapy clinical development

Over 18,000 patients from 70 countries have participated in 210 cell and gene therapy trials since 2012. These advances in cell and gene therapy represent innovative treatments, particularly where traditional methods fall short, but require navigating new risks. Our multidisciplinary teams are ready to deliver life-changing treatments to patients sooner.

A broad range of experience and a proven track record of success

We have a unique perspective across the landscape of Cell and Gene Therapy (CAGT). Working extensively with biotech and large pharma clients, we draw upon our broad experiences to craft tailored solutions to help sponsors optimize and accelerate their clinical development.

This is who we are, what we do, and how we're different.

Drive smarter decisions with IQVIA Connected Intelligence

Our powerful approach brings together CAGT experts, data-driven insights, global site networks, and innovative technologies to help you drive smarter decisions to accelerate CAGT clinical development.

Therapeutic expertise — hands-on and hand-selected for biotech

Therapeutically aligned solutions to advance your clinical program to the next milestone.

The Bespoke Gene Therapy Consortium
IQVIA's commitment to shifting the paradigm in rare disease and cell and gene therapies includes leveraging the BGTC's regulatory playbook. The playbook serves as a guiding framework to expedite the delivery of therapies to patients.

We are actively collaborating with industry and nonprofit partners to develop standardized platform-based approaches and streamline navigation of the regulatory pathway. This ongoing effort aims to advance the clinical development landscape for rare diseases.

Related solutions

Contact Us